Cuba encouraged by early efficacy results of homegrown COVID-19 vaccine - Reuters

A nurse shows a dose of the Soberana-02 COVID-19 vaccine to be used in a volunteer as part of Phase III trials of the experimental Cuban vaccine candidate, amid concerns about the spread of the coronavirus disease (COVID-19), in Havana, Cuba, March 31, 2021.

HAVANA, June 19 (Reuters) - Cuba's Soberana 2 vaccine candidate has shown 62% efficacy with just two of its three doses, state-run biopharmaceutical corporation BioCubaFarma said on Saturday, citing preliminary data from late phase trials.

Cuba, whose biotech sector has exported vaccines for decades, has five vaccine candidates in clinical trials, of which two - Soberana 2 and Abdala - are in late phase trials.